Emerging research suggest Retatru tide , a dual agonist targeting both GLP-1 and GIP , may provide a promising step forward for body management . Early clinical trials have demonstrated substantial losses in abdominal mass , conceivably outperforming other body composition treatments. However , additional study is required to thoroughly assess its